Personal Genome Services Market Report 2026

The personal genome services market size has grown rapidly in recent years. It will grow from $6.84 billion in 2025 to $7.85 billion in 2026 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to falling sequencing costs, rise in ancestry testing demand, growth in consumer genetics awareness, expansion of genomics startups, improved sequencing accuracy.

The personal genome services market size is expected to see rapid growth in the next few years. It will grow to $13.69 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to growth in preventive genomics adoption, expansion of pharmacogenomics usage, rising personalized wellness demand, broader insurance supported testing, integration with digital health platforms. Major trends in the forecast period include direct to consumer genome testing, integrated health risk genomic reports, pharmacogenomic service bundles, preventive genome screening packages, digital genetic counseling platforms.

The increasing focus on personalized medicine is anticipated to drive the growth of the personal genome services market in the coming years. Personalized medicine refers to a medical approach that customizes treatment and prevention strategies based on an individual’s genetic, biological, and lifestyle characteristics. The adoption of personalized medicine is rising due to advances in genomics and molecular diagnostics, which enable treatments to be tailored according to an individual’s genetic profile for improved outcomes. Personal genome services support personalized medicine by analyzing an individual’s genetic makeup to assess disease risk, guide drug selection, and tailor prevention and treatment strategies. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing focus on personalized medicine is driving the growth of the personal genome services market.

Companies operating in the personal genome services market are focusing on developing advanced solutions such as genome-wide risk stratification to provide personalized health insights, predict disease susceptibility, and guide preventive and lifestyle interventions. Genome-wide risk stratification refers to the process of analyzing an individual’s entire genome to identify genetic variations that contribute to the risk of developing certain diseases or conditions, enabling personalized predictions of health risks and targeted preventive strategies. For example, in November 2025, MyOme Inc., a US-based biotechnology company, launched the first integrated polygenic risk score (iPRS) test for prostate cancer. It combines approximately 7 million genetic markers with clinical factors to deliver personalized 10-year and lifetime risk estimates, validated in more than 140,000 diverse men. Its purpose is early detection and prevention for 95% of cases without rare variants such as BRCA2, guiding PSA, MRI, or biopsies for high-risk individuals (3-4x elevated odds in top decile) while cutting false positives and overtreatment. Benefits include precise stratification, equitable performance across ancestries, and lifelong AI-updated insights from one whole-genome sample.

In March 2025, Tempus AI Inc., a US-based health technology company, acquired Ambry Genetics Corp. for an undisclosed sum. Through this acquisition, Tempus AI seeks to enhance its precision medicine platform by integrating Ambry Genetics’ expertise in hereditary cancer screening, pediatrics, rare diseases, immunology, reproductive health, and cardiology with its AI capabilities to identify patients early, support treatments, monitor disease progression, and drive clinical innovation. Ambry Genetics Corp. is a US-based provider of clinical genetic testing services, offering hereditary cancer, rare disease, and personalized genomic insights.

Major companies operating in the personal genome services market are Thermo Fisher Scientific Inc, Illumina Inc, Helix OpCo LLC, Ancestry.com Operations Inc, Fulgent Genetics Inc, 23andMe Holding Co, Prenetics Global Limited, MyHeritage Ltd, Color Health Inc, Genomics plc, GenoPalate Inc, Living DNA Ltd, Mapmygenome India Pvt Ltd, Nebula Genomics Inc, Xcode Life Sciences Pvt Ltd, Sema4 Holdings Corp, Gene by Gene Ltd, TellmeGen SL, CRI Genetics LLC, African Ancestry Inc, and DNAFit Limited.

Tariffs on sequencing instruments, lab consumables, and bioinformatics hardware are raising operational costs in the personal genome services market. Whole genome and advanced sequencing segments are most affected due to imported platforms and reagents. Smaller labs in import dependent regions face tighter margins. These costs can influence consumer test pricing. At the same time, tariffs are encouraging regional sequencing infrastructure and local reagent production.

The personal genome services market research report is one of a series of new reports that provides personal genome services market statistics, including personal genome services industry global market size, regional shares, competitors with a personal genome services market share, detailed personal genome services market segments, market trends and opportunities, and any further data you may need to thrive in the personal genome services industry. This personal genome services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Personal genome services refer to direct-to-consumer or clinical offerings that analyze an individual’s complete or partial genetic information using genomic sequencing and bioinformatics tools to provide insights on health risks, inherited traits, disease susceptibility, drug response, ancestry, and personalized wellness guidance. These services aid individuals and healthcare providers in making informed decisions about preventive care, lifestyle modifications, medical treatments, and family planning based on a person’s unique genetic profile.

The principal service types of personal genome services include genetic testing, whole genome sequencing, carrier testing, ancestry testing, and other related services. Genetic testing analyzes an individual’s DNA to identify variations linked to health, traits, or ancestry. These services are applied in healthcare, research, ancestry studies, and other areas, catering to end users including hospitals, clinics, research centers, direct-to-consumer platforms, and other relevant recipients.

The personal genome services market includes revenues earned by entities through genetic testing services, whole genome sequencing services, exome sequencing services, ancestry analysis services, health risk assessment services, carrier screening services, pharmacogenomic testing services, wellness reporting services, trait analysis services, and personalized nutrition recommendations. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.